EDIVOXETINE HYDROCHLORIDE

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C18H26FNO4.ClH
Molecular Weight	375.863
Optical Activity	UNSPECIFIED
Defined Stereocenters	2 / 2
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

Cl.[H][C@]1(CNCCO1)[C@@](O)(CC2=CC(F)=CC=C2OC)C3CCOCC3

InChI

InChIKey=WJDKGRLMNSHPON-CJRXIRLBSA-N

InChI=1S/C18H26FNO4.ClH/c1-22-16-3-2-15(19)10-13(16)11-18(21,14-4-7-23-8-5-14)17-12-20-6-9-24-17;/h2-3,10,14,17,20-21H,4-9,11-12H2,1H3;1H/t17-,18+;/m0./s1

HIDE SMILES / InChI

Molecular Formula	ClH
Molecular Weight	36.461
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Molecular Formula	C18H26FNO4
Molecular Weight	339.4017
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	2 / 2
E/Z Centers	0
Optical Activity	UNSPECIFIED

Description
Sources: https://adisinsight.springer.com/drugs/800026152 | https://www.ncbi.nlm.nih.gov/pubmed/27035159 | https://www.ncbi.nlm.nih.gov/pubmed/28402139 | https://www.ncbi.nlm.nih.gov/pubmed/21511276

Edivoxetine (LY-2216684) is a highly selective norepinephrine reuptake inhibitor. It is under development as adjunctive or monotherapy of disorders believed to be associated with alterations in norepinephrine transmission within the central nervous system. Currently, edivoxetine is being studied in the treatment of attention-deficit hyperactivity disorder. Edivoxetine development in the treatment of major depressive disorder has been discontinued.

CNS Activity

Originator

Approval Year

PubMed

Title	Date	PubMed
A randomized, double-blind study comparing LY2216684 and placebo in the treatment of major depressive disorder.	2011 Jun	21511276

Sample Use Guides

In Vivo Use Guide

Open-label study of edivoxetine once daily dosing (0.1-0.3 mg/kg) as treatment for ADHD in children (6-11 years) and adolescents (12-17 years) to assess safety for up to 5 years. The efficacy, tolerability, and safety of edivoxetine were studied in adult patients with major depressive disorder (MDD). This randomized, double-blind study compared flexible-dose edivoxetine 6-18 mg once daily with placebo for 10 weeks acute therapy followed by 1 year edivoxetine treatment

Route of Administration: Oral

Substance Class	Chemical Created by `admin` on `Fri Dec 15 18:56:12 GMT 2023` Edited by `admin` on `Fri Dec 15 18:56:12 GMT 2023`
Record UNII	CP012282EU
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

EDIVOXETINE HYDROCHLORIDE

Official Name

English

EDIVOXETINE HYDROCHLORIDE [USAN]

Common Name

English

LY2216684 HCL

Code

English

2-MORPHOLINEMETHANOL, .ALPHA.-((5-FLUORO-2-METHOXYPHENYL)METHYL)-.ALPHA.-(TETRAHYDRO-2H-PYRAN- 4-YL)-, HYDROCHLORIDE (1:1), (.ALPHA.R,2S)-

Common Name

English

(1R)-2-(5-FLUORO-2-METHOXYPHENYL)-1-((2S)-MORPHOLIN-2-YL)-1-(TETRAHYDRO-2H-PYRAN-4- YL)ETHANOL HYDROCHLORIDE

Systematic Name

English

LY-2216684 HCL

Code

English

Edivoxetine hydrochloride [WHO-DD]

Common Name

English

Code System Code Type Description

FDA UNII

CP012282EU